You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Email: firstname.lastname@example.org Phone: +41 22 560 60 75
24 March 2017, Johannesburg, South Africa
Clinical access programme for an MDR-TB medicine launched in South Africa.
31 October 2016, Geneva, Switzerland
The Stop TB Partnership announced Otsuka’s new anti-tuberculosis (TB) compound, to be developed as part of a pan-TB regimen.
8 May 2015, Geneva Switzerland
The WHO published the new edition of its Model List of Essential Medicines, which includes new treatments for multidrug-resistant (MDR-TB).
1 May 2015, Geneva, Switzerland
The WHO released an updated companion handbook to the WHO guidelines for the programmatic management of drug-resistant TB.
25 February, 2016, Munich, Germany
Stop TB Partnership’s Global Drug Facility and Otsuka announce a new private-public partnership to expand worldwide access to an MDR-TB drug.
16 July 2015, Tokyo, Japan
Efficacy results of Otsuka’s drug for extensively drug-resistant TB (XDR-TB) published in the New England Journal of Medicine.
4 July 2014, Tokyo, Japan
The Japanese Ministry of Health, Labour and Welfare approved a medicine developed by Otsuka for treatment of adults with pulmonary MDR-TB.
30 April 2014, Tokyo, Japan
Otsuka Wins European Marketing Authorization for a medicine to treat adult pulmonary MDR-TB.
Information current as of 26-06-2017